Sonesitatug Vedotin Granted Priority Review in the US
The application covers second- and later-line treatment of patients with CLDN18.2-positive advanced gastric or gastroesophageal junction cancers.
The application covers second- and later-line treatment of patients with CLDN18.2-positive advanced gastric or gastroesophageal junction cancers.